Investors focused on the Medical space have likely heard of Aytu Bioscience (AYTU - Free Report) , but is the stock performing well in comparison to the rest of its sector peers? A quick glance at the company's year-to-date performance in comparison to the rest of the Medical sector should help us answer this question.
Aytu Bioscience is one of 904 individual stocks in the Medical sector. Collectively, these companies sit at #4 in the Zacks Sector Rank. The Zacks Sector Rank includes 16 different groups and is listed in order from best to worst in terms of the average Zacks Rank of the individual companies within each of these sectors.
The Zacks Rank is a proven model that highlights a variety of stocks with the right characteristics to outperform the market over the next one to three months. The system emphasizes earnings estimate revisions and favors companies with improving earnings outlooks. AYTU is currently sporting a Zacks Rank of #2 (Buy).
Over the past 90 days, the Zacks Consensus Estimate for AYTU's full-year earnings has moved 129.63% higher. This is a sign of improving analyst sentiment and a positive earnings outlook trend.
Our latest available data shows that AYTU has returned about 40.87% since the start of the calendar year. In comparison, Medical companies have returned an average of 1.84%. This shows that Aytu Bioscience is outperforming its peers so far this year.
Breaking things down more, AYTU is a member of the Medical - Biomedical and Genetics industry, which includes 393 individual companies and currently sits at #63 in the Zacks Industry Rank. On average, stocks in this group have gained 11.68% this year, meaning that AYTU is performing better in terms of year-to-date returns.
AYTU will likely be looking to continue its solid performance, so investors interested in Medical stocks should continue to pay close attention to the company.
Zacks Names "Single Best Pick to Double"
From thousands of stocks, 5 Zacks experts each have chosen their favorite to skyrocket +100% or more in months to come. From those 5, Director of Research Sheraz Mian hand-picks one to have the most explosive upside of all.
It’s a little-known chemical company that’s up 65% over last year, yet still dirt cheap. With unrelenting demand, soaring 2022 earnings estimates, and $1.5 billion for repurchasing shares, retail investors could jump in at any time.
This company could rival or surpass other recent Zacks’ Stocks Set to Double like Boston Beer Company which shot up +143.0% in little more than 9 months and NVIDIA which boomed +175.9% in one year.
Free: See Our Top Stock and 4 Runners Up >>
Investors focused on the Medical space have likely heard of Aytu Bioscience (AYTU - Free Report) , but is the stock performing well in comparison to the rest of its sector peers? A quick glance at the company's year-to-date performance in comparison to the rest of the Medical sector should help us answer this question.
Aytu Bioscience is one of 904 individual stocks in the Medical sector. Collectively, these companies sit at #4 in the Zacks Sector Rank. The Zacks Sector Rank includes 16 different groups and is listed in order from best to worst in terms of the average Zacks Rank of the individual companies within each of these sectors.
The Zacks Rank is a proven model that highlights a variety of stocks with the right characteristics to outperform the market over the next one to three months. The system emphasizes earnings estimate revisions and favors companies with improving earnings outlooks. AYTU is currently sporting a Zacks Rank of #2 (Buy).
Over the past 90 days, the Zacks Consensus Estimate for AYTU's full-year earnings has moved 129.63% higher. This is a sign of improving analyst sentiment and a positive earnings outlook trend.
Our latest available data shows that AYTU has returned about 40.87% since the start of the calendar year. In comparison, Medical companies have returned an average of 1.84%. This shows that Aytu Bioscience is outperforming its peers so far this year.
Breaking things down more, AYTU is a member of the Medical - Biomedical and Genetics industry, which includes 393 individual companies and currently sits at #63 in the Zacks Industry Rank. On average, stocks in this group have gained 11.68% this year, meaning that AYTU is performing better in terms of year-to-date returns.
AYTU will likely be looking to continue its solid performance, so investors interested in Medical stocks should continue to pay close attention to the company.
Zacks Names "Single Best Pick to Double"
From thousands of stocks, 5 Zacks experts each have chosen their favorite to skyrocket +100% or more in months to come. From those 5, Director of Research Sheraz Mian hand-picks one to have the most explosive upside of all.
It’s a little-known chemical company that’s up 65% over last year, yet still dirt cheap. With unrelenting demand, soaring 2022 earnings estimates, and $1.5 billion for repurchasing shares, retail investors could jump in at any time.
This company could rival or surpass other recent Zacks’ Stocks Set to Double like Boston Beer Company which shot up +143.0% in little more than 9 months and NVIDIA which boomed +175.9% in one year.
Free: See Our Top Stock and 4 Runners Up >>
Get the latest research report on AYTU - FREE